Delcath Systems (DCTH) Stock Price

Delcath Systems Price

NASDAQ·CLOSED
12.81USD+0.22 (+1.73 %)
Market closed

Over the last 13 years Delcath Systems grew revenue by 52.7% annually, reaching 85.23 M USD. For Delcath Systems, the net margin of 3.2% is up versus -721.5% a few years ago. The consensus 12-month price target for Delcath Systems is 22.44 USD, about 75.2% above where the stock trades today. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus. Delcath Systems's share price has gained 12.4% over the last twelve months. The stock trades about 56% above its 52-week low.

Delcath Systems stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Delcath Systems over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Delcath Systems stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Delcath Systems's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Delcath Systems Stock Price History
DateDelcath Systems Price
7/21/202612.81 USD
7/20/202612.59 USD
7/17/202612.81 USD
7/16/202612.85 USD
7/15/202613.18 USD
7/14/202613.14 USD
7/13/202613.06 USD
7/10/202613.01 USD
7/9/202613.52 USD
7/8/202612.99 USD
7/7/202613.44 USD
7/6/202613.38 USD
7/2/202613.20 USD
7/1/202612.91 USD
6/30/202612.59 USD
6/29/202612.95 USD
6/26/202612.94 USD
6/25/202612.32 USD
6/24/202612.24 USD
6/23/202612.29 USD
6/22/202611.55 USD
6/18/202611.73 USD
6/17/202612.02 USD
6/16/202611.58 USD
6/15/202611.93 USD
6/12/202611.87 USD
6/11/202611.57 USD
6/10/202611.63 USD
6/9/202611.69 USD
6/8/202610.94 USD
6/5/202610.67 USD
6/4/202610.79 USD
6/3/202610.33 USD
6/2/202610.53 USD
6/1/202610.60 USD
5/29/202610.78 USD
5/28/202610.95 USD
5/27/202610.91 USD
5/26/202610.83 USD
5/22/202611.02 USD
5/21/202611.45 USD
5/20/202611.23 USD
5/19/202610.85 USD
5/18/202611.09 USD
5/15/202611.07 USD
5/14/202611.46 USD
5/13/202611.61 USD
5/12/202611.34 USD
5/11/202611.06 USD
5/8/202611.48 USD
5/7/202611.24 USD
5/6/202611.26 USD
5/5/202611.53 USD
5/4/202611.02 USD
5/1/202610.80 USD
4/30/202610.38 USD
4/29/202610.21 USD
4/28/202610.55 USD
4/27/202610.84 USD
4/24/202610.84 USD
4/23/202610.64 USD
4/22/202611.19 USD
4/21/202610.66 USD
4/20/202610.88 USD
4/17/202610.86 USD
4/16/202610.83 USD
4/15/202610.99 USD
4/14/202610.88 USD
4/13/202610.45 USD
4/10/202610.04 USD
4/9/20269.88 USD
4/8/20269.85 USD
4/7/20269.67 USD
4/6/20269.70 USD
4/2/20269.63 USD
4/1/20269.54 USD
3/31/20269.54 USD
3/30/20269.28 USD
3/29/20268.89 USD
3/27/20268.97 USD
3/26/20268.97 USD
3/25/20269.13 USD
3/24/20269.20 USD
3/23/20268.98 USD
3/22/20269.10 USD
3/20/20269.07 USD
3/19/20269.07 USD
3/18/20269.34 USD
3/17/20269.38 USD
3/16/20269.74 USD
3/15/20269.81 USD
3/13/20269.45 USD
3/12/20269.45 USD
3/11/20269.48 USD
3/10/20269.68 USD
3/9/20269.37 USD
3/8/20269.12 USD
3/6/20269.08 USD
3/5/20269.08 USD
3/4/20269.08 USD
3/3/20269.23 USD
3/2/20268.60 USD
3/1/20268.93 USD
2/27/20268.90 USD
2/26/20268.90 USD
2/25/20269.00 USD
2/24/202610.21 USD
2/23/20269.95 USD
2/22/20269.74 USD
2/20/20269.78 USD
2/19/20269.78 USD
2/18/20269.53 USD
2/17/20269.48 USD
2/16/20269.40 USD
2/13/20269.31 USD
2/12/20269.31 USD
2/11/20269.12 USD
2/10/20269.50 USD
2/9/202610.10 USD
2/8/20269.95 USD
2/6/20269.37 USD
2/5/20269.37 USD
2/4/20268.94 USD
2/3/20269.70 USD
2/2/20269.97 USD
2/1/20269.98 USD
1/30/20269.91 USD
1/29/20269.91 USD
1/28/20269.91 USD
1/27/20269.92 USD
1/26/202610.21 USD
1/25/202610.55 USD
1/23/202610.53 USD
1/22/202610.53 USD
1/21/202610.98 USD
1/20/202610.34 USD
1/19/202610.19 USD
1/16/202610.37 USD
1/15/202610.37 USD
1/14/202610.21 USD
1/13/202610.38 USD
1/12/202610.42 USD
1/11/202610.29 USD
1/9/202610.34 USD
1/8/202610.34 USD
1/7/202610.21 USD
1/6/202610.53 USD
1/5/202610.45 USD
1/4/202610.26 USD
1/2/20269.95 USD
1/1/20269.95 USD
12/31/202510.10 USD
12/30/202510.10 USD
12/29/202510.15 USD
12/28/202510.17 USD
12/26/202510.30 USD
12/25/202510.30 USD
12/24/202510.32 USD
12/23/202510.32 USD
12/22/202510.12 USD
12/21/202510.07 USD
12/19/202510.06 USD
12/18/202510.06 USD
12/17/20259.93 USD
12/16/20259.96 USD
12/15/202510.03 USD
12/14/202510.08 USD
12/12/202510.37 USD
12/11/202510.37 USD
12/10/202510.39 USD
12/9/20259.92 USD
12/8/20259.91 USD
12/7/20259.64 USD
12/5/20259.78 USD
12/4/20259.78 USD
12/3/202510.02 USD
12/2/20259.66 USD
12/1/20259.31 USD
11/30/20259.58 USD
11/28/20259.70 USD
11/27/20259.70 USD
11/26/20259.64 USD
11/25/20259.64 USD
11/24/20259.23 USD
11/23/20259.23 USD
11/21/20258.96 USD
11/20/20258.96 USD
11/19/20258.19 USD
11/18/20258.51 USD
11/17/20258.65 USD
11/16/20258.61 USD
11/14/20258.93 USD
11/13/20258.93 USD
11/12/20258.61 USD
11/11/20258.59 USD
11/10/20258.62 USD
11/9/20258.58 USD
11/7/20258.64 USD
11/6/20258.64 USD
11/5/20258.64 USD
11/4/20258.68 USD
11/3/20259.08 USD
11/2/20259.52 USD
10/31/20259.83 USD
10/30/20259.83 USD
10/29/20259.40 USD
10/28/20259.72 USD
10/27/202510.15 USD
10/26/20259.99 USD
10/23/202510.23 USD
10/22/202510.38 USD
10/21/202510.36 USD
10/20/202511.39 USD
10/19/202511.42 USD
10/16/202511.97 USD
10/15/202512.36 USD
10/14/202511.32 USD
10/13/202511.37 USD
10/12/202511.35 USD
10/9/202510.46 USD
10/8/202510.88 USD
10/7/202511.10 USD
10/6/202510.80 USD
10/5/202510.80 USD
10/2/202511.10 USD
10/1/202510.65 USD
9/30/202510.75 USD
9/29/202510.75 USD
9/28/202510.90 USD
9/25/202510.75 USD
9/24/202510.86 USD
9/23/202511.03 USD
9/22/202511.00 USD
9/21/202511.55 USD
9/18/202511.54 USD
9/17/202511.75 USD
9/16/202511.20 USD
9/15/202511.02 USD
9/14/202510.67 USD
9/11/202510.84 USD
9/10/202511.13 USD
9/9/202511.12 USD
9/8/202511.60 USD
9/7/202511.55 USD
9/4/202511.65 USD
9/3/202511.10 USD
9/2/202510.90 USD
9/1/202510.90 USD
8/28/202511.02 USD
8/27/202510.88 USD
8/26/202510.94 USD
8/25/202511.12 USD
8/24/202510.89 USD
8/21/202511.12 USD
8/20/202510.41 USD
8/19/202510.33 USD
8/18/202510.56 USD
8/17/202510.65 USD
8/14/202510.36 USD
8/13/202510.47 USD
8/12/202511.11 USD
8/11/202510.88 USD
8/10/202510.51 USD
8/7/202510.01 USD
8/6/202510.19 USD
8/5/202510.64 USD
8/4/202510.52 USD
8/3/202511.27 USD
7/31/202510.59 USD
7/30/202510.75 USD
7/29/202510.93 USD
7/28/202510.91 USD
7/27/202511.41 USD
7/24/202511.41 USD
Access this data via the Eulerpool API
Get Free API Key

Delcath Systems Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.65 M USD
-23.98 M USD
-24.16 M USD
Jan 1, 2021
3.56 M USD
-24.46 M USD
-25.65 M USD
Jan 1, 2022
2.72 M USD
-33.82 M USD
-36.51 M USD
Jan 1, 2023
2.07 M USD
-45.58 M USD
-47.68 M USD
Jan 1, 2024
37.21 M USD
-12.41 M USD
-26.39 M USD
Jan 1, 2025
85.23 M USD
660,000.00 USD
2.70 M USD
Jan 1, 2026 (e)
103.24 M USD
19.38 M USD
-17.25 M USD
Jan 1, 2027 (e)
130.63 M USD
39.12 M USD
-14.54 M USD

Delcath Systems Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 8:13 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
––1.001.001.002.003.001.001.003.002.002.0037.0085.00103.00130.00
–––––100.0050.00-66.67–200.00-33.33–1,750.00129.7321.1826.21
––7,300.00100.00100.00100.0066.677,300.00100.0066.67100.0050.0083.7885.8885.8885.88
73.0073.0073.001.001.002.002.0073.001.002.002.001.0031.0073.0088.46111.65
-53.00-33.00-19.00-15.00-16.00-23.00-27.00-4.00-23.00-24.00-33.00-45.00-12.00–19.0039.00
––-1,900.00-1,500.00-1,600.00-1,150.00-900.00-400.00-2,300.00-800.00-1,650.00-2,250.00-32.43–18.4530.00
-51.00-30.00-17.00-14.00-17.00-45.00-19.00-8.00-24.00-25.00-36.00-47.00-26.002.00-17.00-14.00
70.00-41.18-43.33-17.6521.43164.71-57.78-57.89200.004.1744.0030.56-44.68-107.69-950.00-17.65
4.007.009.001.002.0039.850.110.104.967.829.8622.9728.4539.8539.8539.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Delcath Systems generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Delcath Systems retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Delcath Systems's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Delcath Systems has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Delcath Systems's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Delcath Systems stock margins

The Delcath Systems margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Delcath Systems. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Delcath Systems.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
61.12 %
-1,456.93 %
-1,467.56 %
Jan 1, 2021
81.13 %
-688.13 %
-721.49 %
Jan 1, 2022
74.77 %
-1,243.95 %
-1,342.70 %
Jan 1, 2023
69.25 %
-2,207.22 %
-2,308.86 %
Jan 1, 2024
83.37 %
-33.36 %
-70.92 %
Jan 1, 2025
86.16 %
0.77 %
3.17 %
Jan 1, 2026 (e)
86.16 %
18.77 %
-16.71 %
Jan 1, 2027 (e)
86.16 %
29.95 %
-11.13 %

Delcath Systems Stock Revenue, EBIT, Earnings per Share

The Delcath Systems earnings per share therefore indicates how much revenue Delcath Systems has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.33 USD
-4.84 USD
-4.87 USD
Jan 1, 2021
0.45 USD
-3.13 USD
-3.28 USD
Jan 1, 2022
0.28 USD
-3.43 USD
-3.70 USD
Jan 1, 2023
0.09 USD
-1.98 USD
-2.08 USD
Jan 1, 2024
1.31 USD
-0.44 USD
-0.93 USD
Jan 1, 2025
2.14 USD
0.02 USD
0.07 USD
Jan 1, 2026 (e)
3.62 USD
0.49 USD
-0.61 USD
Jan 1, 2027 (e)
4.58 USD
0.98 USD
-0.51 USD

Delcath Systems business model & stock analysis

Delcath Systems Inc is a US-American medical technology company specializing in the development of innovative products for the treatment of various forms of liver cancer. The company was founded in 1988 in New York and is headquartered in Queensbury today.

Delcath Systems SWOT Analysis

Strengths

Delcath Systems Inc has developed a unique medical technology called the Delcath Hepatic Delivery System, which allows for targeted delivery of high-dose chemotherapy to the liver.

The company's technology provides a more effective treatment option for patients with liver cancer and other liver-dominant metastases.

Weaknesses

One of the main weaknesses of Delcath Systems Inc is its heavy reliance on a single product, the Delcath Hepatic Delivery System.

The company may face challenges if competitors develop similar technologies or if the demand for their product decreases.

Opportunities

The increasing incidence of liver cancer and the need for more effective treatment options provide Delcath Systems Inc with significant growth opportunities.

The company can also explore partnerships with pharmaceutical companies to expand the use of their technology in other areas of oncology.

Threats

Competition from established medical device companies and other emerging technologies is a major threat to Delcath Systems Inc.

The strict regulatory environment and the need for extensive clinical trials could impact the company's ability to bring new products to market in a timely manner.

Delcath Systems Segments

Delcath Systems Revenue by Segment (1/2)

  • 3 Years

  • Max

HEPZATO KIT
CHEMOSAT
Product
Product revenue
Product and Service, Other
Other revenue
Details
Date
HEPZATO KIT
CHEMOSAT
Product
Product revenue
Product and Service, Other
Other revenue
Jan 1, 2022
0.00 USD
0.00 USD
2.55 M USD
0.00 USD
171,000.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
2.07 M USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
4.90 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
78.84 M USD
6.40 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Delcath Systems Revenue by Segment (2/2)

  • Max

HEPZATO KIT
Details
Date
HEPZATO KIT
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
32.30 M USD
Jan 1, 2025
0.00 USD

Delcath Systems Revenue by Region

  • Max

United States
Foreign
Details
Date
United States
Foreign
Jan 1, 2025
78.84 M USD
6.40 M USD

Delcath Systems Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Delcath Systems historical P/E ratio, EBIT multiple, and P/S ratio

Delcath Systems annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Delcath Systems shares outstanding

The number of shares of Delcath Systems was 39.85 M in 2025. This indicates how many shares Delcath Systems is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
4.96 M Stocks
Jan 1, 2021
7.82 M Stocks
Jan 1, 2022
9.86 M Stocks
Jan 1, 2023
22.97 M Stocks
Jan 1, 2024
28.45 M Stocks
Jan 1, 2025
39.85 M Stocks
Jan 1, 2026 (e)
39.85 M Stocks
Jan 1, 2027 (e)
39.85 M Stocks

Delcath Systems stock splits

In Delcath Systems's history, there have been no stock splits.

Current Delcath Systems forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy92.31 % (12)
Hold7.69 % (1)
Sell0.00 % (0)
12M Price Target
22.44
Last Price
12.43
Currency
USD
12M Return Potential
80.53 %
LTM Return
0 %

Delcath Systems Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/10/2026-0.09USD26.78 MUSD2026 Q2
8/4/2026-0.09USD26.78 MUSD2026 Q2
5/12/2026-0.09USD23.85 MUSD2026 Q1
5/6/2026-0.09USD23.85 MUSD2026 Q1
3/4/2026-0.06USD20.60 MUSD2025 Q4
2/26/2026-0.06USD20.73 MUSD2025 Q4
11/12/2024-0.20USD10.67 MUSD2024 Q3
11/11/2024-0.23USD9.66 MUSD2024 Q3
5/10/2024-0.46USD1.81 MUSD2024 Q1
3/25/2024-0.52USD551,208.00USD2023 Q4

Delcath Systems shareholder structure

% Name
11.57568%
Rosalind Advisors, Inc.
Rosalind Advisors, Inc.
5.64944%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.46298%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
2.84995%
Deerfield Management Company, L.P.
Deerfield Management Company, L.P.
2.81715%
Citadel Advisors LLC
Citadel Advisors LLC
2.46628%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Delcath Systems Executives and Management Board

GM

Mr. Gerard Michel

(61)

Chief Executive Officer, Director · since 2020

Compensation2.16 M USD
VV

Dr. Vojislav Vukovic

(58)

Chief Medical Officer

Compensation1.09 M USD
KM

Mr. Kevin Muir

(53)

General Manager - Interventional Oncology

Compensation1.02 M USD
MR

Dr. Martha Rook

(54)

Chief Operating Officer

Compensation933,097.00 USD
JS

Mr. John Sylvester

(61)

Independent Non-Executive Chairman of the Board

Compensation229,169.00 USD

Delcath Systems Supply Chain

Frequently asked questions about Delcath Systems

Delcath Systems Inc is a medical technology company specializing in targeted therapies for the treatment of various forms of cancer. Their business model revolves around providing innovative solutions that enable physicians to safely deliver high doses of chemotherapeutic agents directly to the affected organs, while minimizing exposure to healthy tissues. Delcath Systems' proprietary system, known as Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Delcath HDS), offers significant advancements in cancer treatment by enhancing drug delivery precision and reducing systemic side effects. This targeted delivery approach holds immense potential in improving patient outcomes and is at the forefront of Delcath Systems' mission to revolutionize cancer treatment.

All fundamentals and in-depth analysis of Delcath Systems

Our stock analysis for Delcath Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Delcath Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Delcath Systems Stock
Delcath Systems Revenue→
Delcath Systems Stock
Delcath Systems Net Income→
Delcath Systems Stock
Delcath Systems P/E→
Delcath Systems Stock
Delcath Systems P/S→
Delcath Systems Stock
Delcath Systems EBIT→
Delcath Systems Stock
Delcath Systems Dividend→
Delcath Systems Stock
Delcath Systems Directors Dealings→
Delcath Systems Stock
Delcath Systems Stocks→
Delcath Systems Stock
Delcath Systems Market capitalization→
Delcath Systems Stock
Delcath Systems Debt→
Delcath Systems Stock
Delcath Systems Liabilities→
Delcath Systems Stock
Delcath Systems Equity→
Delcath Systems Stock
Delcath Systems AAQS→
Delcath Systems Stock
Delcath Systems Employees→
Delcath Systems Stock
Delcath Systems ROE→
Delcath Systems Stock
Delcath Systems ROA→
Delcath Systems Stock
Delcath Systems ROCE→
Delcath Systems Stock
Delcath Systems News→
Delcath Systems Stock
Delcath Systems Analyst Price Targets→

Health Stocks

Delivra Health BrandsDefinium TherapeuticsDelta Asia InternationalDefinitive HealthcareDelta-Fly PharmaDefence TherapeuticsDemant A/SDeepNoidDenali TherapeuticsDedicare AB (publ)Denis Chem LabDecoy TherapeuticsAll Stocks A–Z →